A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Kurteya nûçeyê
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Nûçeyên dawî yên weşangerên pêbawer bi kurtasî bişopîne. Ji bo hûrguliyan lînka çavkaniya orîjînal veke.